Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)

Study Identifier
CMO-MA-EYE-0564
CT.gov Identifier
NCT03889444
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Statistical Analysis Plan
Available Language(s): English
Download document(s)
Protocol
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Macular Edema
    • Study Drug
  • Dexamethasone intravitreal implant
    • Phase
    N/A
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Participant received at least two Ozurdex® implants in the study eye to treat visual impairment due to DME * First Ozurdex® implant injection occurred after 1 January 2015 * Participant was followed-up at the site for at least 12 months after the first Ozurdex® implant in the study eye
    Exclusion Criteria:
    \- Participant received Ozurdex® implants as part or during a clinical study

    Protocol Summary

    A retrospective, non-interventional, observational, multi-center, drug utilization study to be conducted in adult participants with visual impairment due to DME treated with Ozurdex implants in Germany and Switzerland from 1 January 2015 to 1 September 2017.

    Study Locations

    Location
    Status
    Location
    Clinical Trials Registry Team
    Irvine, California, United States, 92622
    Status
    Not applicable